Renal Cell Carcinoma (RCC) Clinical Trials

18 recruiting

Renal Cell Carcinoma (RCC) Trials at a Glance

19 actively recruiting trials for renal cell carcinoma (rcc) are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in New Haven, Philadelphia, and Cleveland. Lead sponsors running renal cell carcinoma (rcc) studies include Bristol-Myers Squibb, Chongqing Precision Biotech Co., Ltd, and Alliance for Clinical Trials in Oncology.

Browse renal cell carcinoma (rcc) trials by phase

Treatments under study

About Renal Cell Carcinoma (RCC) Clinical Trials

Looking for clinical trials for Renal Cell Carcinoma (RCC)? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Cell Carcinoma (RCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Cell Carcinoma (RCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting

Validation of RCC Predicting Model With Emulated-target Trial

Prognostic Cancer ModelRenal Cell Carcinoma (RCC)Prognosis+4 more
Peking University Third Hospital4,700 enrolled1 locationNCT07117227
Recruiting
Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled409 locationsNCT06661720
Recruiting
Not Applicable

CBCT Guided Markerless SBRT for Renal Cell Cancer

Renal Cell Carcinoma (RCC)
Erasmus Medical Center40 enrolled1 locationNCT07402109
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb234 enrolled72 locationsNCT07293351
Recruiting
Phase 3

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Cancer (ccRCC)Renal Cell Carcinoma (Kidney Cancer)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited40 enrolled5 locationsNCT07197580
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Not Applicable

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

Renal Cell Carcinoma (RCC)Nonfunctioning Kidney
Menoufia University60 enrolled1 locationNCT07461090
Recruiting
Not Applicable

Investigation of Lymph Node Biology in Kidney Cancer

Renal Cell Carcinoma (RCC)
Yale University10 enrolled1 locationNCT07038733
Recruiting
Phase 2

Cabozantinib Dose Skipping as an Alternative to Dose Reductions

Renal Cell Carcinoma (RCC)
dr. Tom van der Hulle34 enrolled1 locationNCT07077161
Recruiting
Phase 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting
Not Applicable

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham25 enrolled4 locationsNCT05410509
Recruiting
Phase 1

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Ovarian CancerCervical CancerLung Cancer+3 more
Chongqing Precision Biotech Co., Ltd90 enrolled1 locationNCT07181720
Recruiting
Phase 2

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

Renal Cell Carcinoma (RCC)
Tianjin Medical University Second Hospital40 enrolled1 locationNCT07172386
Recruiting
Phase 2

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Jinling Hospital, China30 enrolled1 locationNCT07175480
Recruiting
Phase 1Phase 2

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Advanced Solid Tumor+3 more
GI Innovation, Inc.76 enrolled3 locationsNCT07172802
Recruiting
Phase 2

Ablative Radioembolization of Renal Cell Carcinoma Trial

Renal Cell Carcinoma (RCC)Radioembolization
Derek W. Cool16 enrolled1 locationNCT06642220
Recruiting
Not Applicable

ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses

Renal Cell Carcinoma (RCC)
University of Florida59 enrolled1 locationNCT06722807
Recruiting

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)
The Affiliated Hospital of Qingdao University40 enrolled1 locationNCT06916624